Literature DB >> 9462382

Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma.

D A Ross1, G D Wilson.   

Abstract

BACKGROUND: Overexpression of the c-myc oncoprotein has been observed to be of prognostic significance in several human cancers. This study was undertaken to establish whether c-myc has any prognostic significance in melanoma.
METHODS: Expression of c-myc oncoprotein was studied in a prospective series of primary and secondary malignant melanomas. Ethanol-fixed tissue was digested into nuclei and stained for flow cytometric analysis using a pan-myc antibody.
RESULTS: Overexpression of the c-myc oncoprotein was prevalent in both disease stages. In primary disease, overexpression was associated with tumour thickness and with the presence of ulceration, age and reduced disease-free interval. Of most importance, high expression of c-myc predicted poor outcome in both primary and metastatic disease. In addition, c-myc was able to discriminate prognosis in melanomas uniformly stratified as thick (greater than 3 mm) lesions.
CONCLUSION: These results indicate an important role for c-myc in melanoma which may lead to better prognostic information and identification of new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9462382     DOI: 10.1046/j.1365-2168.1998.00528.x

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  12 in total

Review 1.  Pathways of oncogene-induced senescence in human melanocytic cells.

Authors:  Rajat Bansal; Mikhail A Nikiforov
Journal:  Cell Cycle       Date:  2010-07-03       Impact factor: 4.534

2.  Increased C-MYC copy numbers on the background of CDKN2A loss is associated with improved survival in nodular melanoma.

Authors:  Denitsa Koynova; Ekaterina Jordanova; Nicole Kukutsch; Pieter van der Velden; Draga Toncheva; Nelleke Gruis
Journal:  J Cancer Res Clin Oncol       Date:  2006-09-15       Impact factor: 4.553

3.  Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma.

Authors:  K Ge; J DuHadaway; W Du; M Herlyn; U Rodeck; G C Prendergast
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

4.  Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression.

Authors:  Delisha A Stewart; Xiaohua Xu; Shelia D Thomas; Donald M Miller; Xiaohou Xu
Journal:  Nucleic Acids Res       Date:  2002-06-01       Impact factor: 16.971

Review 5.  Transcription factors and other dysregulated proteins in melanoma prognosis.

Authors:  J M Karjalainen
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

6.  C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.

Authors:  D Zhuang; S Mannava; V Grachtchouk; W-H Tang; S Patil; J A Wawrzyniak; A E Berman; T J Giordano; E V Prochownik; M S Soengas; M A Nikiforov
Journal:  Oncogene       Date:  2008-08-04       Impact factor: 9.867

7.  The relation between c-myc expression and interferon sensitivity in uveal melanoma.

Authors:  P N Tulley; M Neale; D Jackson; J S Chana; R Grover; I Cree; A O Grobbelaar; G D Wilson
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

8.  Paying "particle" attention to novel melanoma treatment strategies.

Authors:  Michele B Weiss; Andrew E Aplin
Journal:  J Invest Dermatol       Date:  2010-12       Impact factor: 7.590

9.  Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases.

Authors:  G M Kraehn; J Utikal; M Udart; K M Greulich; G Bezold; P Kaskel; U Leiter; R U Peter
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

Review 10.  Biomarkers in melanoma.

Authors:  H Gogas; A M M Eggermont; A Hauschild; P Hersey; P Mohr; D Schadendorf; A Spatz; R Dummer
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.